AN2 Therapeutics, a small molecule biopharmaceutical company, plans to lay off about half of its 41 employees in research, manufacturing, clinical operations, regulatory and quality. Eric Easom, co-founder, chairman, president and CEO of AN2, said: “In the near term, we plan to accelerate our R&D efforts on our boron chemistry platform, where we have several […]